MedTrace Logo

Niraparib for the Treatment of Leiomyosarcoma

NCT05174455 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-09-18

No results posted yet for this study

Summary

This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Conditions

  • Locally Advanced Leiomyosarcoma
  • Metastatic Leiomyosarcoma
  • Stage III Retroperitoneal Sarcoma AJCC v8
  • Stage IIIA Retroperitoneal Sarcoma AJCC v8
  • Stage IIIB Retroperitoneal Sarcoma AJCC v8
  • Stage IV Retroperitoneal Sarcoma AJCC v8
  • Unresectable Leiomyosarcoma

Interventions

DRUG

Niraparib Tosylate Monohydrate

Given PO

Sponsors & Collaborators

  • David Liebner, MD

    lead OTHER

Principal Investigators

  • David Liebner, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-12-31
Completion
2025-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05174455 on ClinicalTrials.gov